NCT05139524|Recruiting
RVF and Other Emerging Infectious Diseases in East and Central Africa
Maintenance and Transmission of Rift Valley Fever Virus and Other Emerging Infectious Diseases in East and Central Africa
Loading search results
Maintenance and Transmission of Rift Valley Fever Virus and Other Emerging Infectious Diseases in East and Central Africa
Sponsor study identifier
Secondary identifiers
NIH
observational
5,000
4 countries
10
Study Start
February 1, 2025
Actual (reported)Primary Completion
May 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one country have been reported over the past 50 years. Within the region, there are specific areas, referred to as hotspots, which support RVF virus maintenance via low-level virus circulation between animals, humans, and mosquitoes. Most outbreaks originate from these hotspots. Our goal is to conduct studies in RVF hotspots in four ECA countries, Kenya, Uganda, Tanzania, and Democratic Republic of Congo (DRC) to determine the burden of RVF disease among humans, wildlife and livestock during inter-epidemic periods (IEPs) and discover circulation of undetected infectious diseases. This information is important for use in developing an early warning system and possibly a vaccination strategy. The study will take place in Uganda, Kenya, Tanzania and Democratic Republic of Congo
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 17, 2021
Actual (reported)December 1, 2021
Actual (reported)February 1, 2025
Actual (reported)May 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Detection of RVF virus exposure
Detection of RVFV RNA, and IgM and IgG antibodies
2 years
Cohort of individuals with acute or reported fever enrolled at health facilities and followed up for upto 24 months.
Individuals enrolled in study as part of a cross sectional survey in the community.
Detection of RVF exposure.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
For health facility based study: Patients attending enrolled health facilities in study areas i.e. North and South Kivu (DRC), Isingiro, Rubanda and Kabale districts (Uganda), Muranga, Isiolo, Tana River and Marsabit counties (Kenya) and Iringa district (Tanzania). For community cross sectional survey: Residents of households in study areas i.e. North and South Kivu (DRC), Isingiro, Rubanda and Kabale districts (Uganda), Muranga, Isiolo, Tana River and Marsabit counties (Kenya) and Iringa district (Tanzania).
Virunga Hospital & North Kivu
Goma, North Kivu, Democratic Republic of the Congo
Hauner A, Benitez AJ, Mulopo-Mukanya N, Roge S, Serrano S, Vanlerberghe V, Lepore L, Esbroeck MV, Masumu J, Nasimiyu C, Njenga MK, Romani MET, Portal YV, Alvarez M, Ramirez-Bartutis R, Guzman MG, Ahuka-Mundeke S, Mukadi-Bamuleka D, Arien KK. Technical validation and implementation of a multiplex real-time PCR for differential diagnostic detection of Zika virus, yellow fever virus, dengue virus and chikungunya virus (ZYDC-PCR). BMC Infect Dis. 2026 Feb 6;26(1):527. doi: 10.1186/s12879-026-12570-w.
Blood
M. Kariuki Njenga, PhD
Washington State University
First Submitted
November 17, 2021
First Posted
December 1, 2021
Study Start
February 1, 2025
Actual (reported)Primary Completion
May 31, 2027
EstimatedRift Valley Fever in Kenya
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
Contact the study team to confirm eligibility.
South Kivu
Bukavu, Democratic Republic of the Congo
Tana River County
Hola, Kenya
Isiolo county
Isiolo, Kenya
Marsabit county
Marsabit, Kenya
Muranga county
Murang’a, Kenya
Iringa
Iringa, Tanzania
Rwekubbo health centre IV & Isingiro district
Isingiro, Uganda
Kabale Regional Referral Hospital & Kabale district
Kabale, Uganda
Rwekubo Health Centre IV & Rubanda district
Rubanda, Uganda
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 5, 2026
Record last verified: 2026-09
There are no plans as yet to make individual participant data available. However, researchers may contact the PI for individual requests.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: